Skip to main navigation Skip to search Skip to main content

Association of cardiometabolic multimorbidity with mortality

  • Emerging Risk Factors Collaboration
  • University of Cambridge
  • Utrecht University
  • University of Glasgow
  • University of Oslo
  • Howard University
  • University of Copenhagen
  • University of Washington
  • University of Western Australia
  • Medical University of South Carolina
  • University of Eastern Finland
  • Metabolic Analytical Services Inc.
  • University of Pittsburgh
  • University of New South Wales
  • University of California at San Diego
  • Norwegian Institute of Public Health
  • Portland State University
  • University of Hawai'i at Mānoa
  • National Institute of Public Health and the Environment
  • National Institute for Health and Welfare
  • Uppsala University
  • University of Groningen
  • University of Gothenburg
  • University of Iowa
  • German Cancer Research Center
  • Institut Pasteur de Lille
  • Baker Heart and Diabetes Institute
  • The University of Osaka
  • Istanbul University
  • City University of New York
  • Boston University
  • University of Southampton
  • University of Oxford
  • Erasmus University Rotterdam
  • Lidköping Hospital
  • Centre de Recherche des Cordeliers
  • Université Paris Cité
  • Harvard University
  • Chiba Prefectural Institute of Public Health
  • Columbia University
  • MedStar Health
  • University of Greifswald
  • German Centre for Cardiovascular Research
  • VU University Medical Centre Amsterdam
  • Innsbruck Medical University
  • Maastricht University
  • Istituto Superiore di Sanita
  • Wageningen University & Research
  • University of Edinburgh
  • Helmholtz Zentrum München - German Research Center for Environmental Health
  • London School of Hygiene and Tropical Medicine
  • University of Padua
  • University of Bristol
  • Cardiff University
  • Ludwig Maximilian University of Munich
  • Assmann-Stiftung für Prävention
  • Institut Universitaire de Cardiologie et Pneumologie de Québec
  • Leiden University
  • The University of Sydney
  • University College London
  • Medical Research Council Epidemiology Unit
  • University of North Carolina at Chapel Hill
  • University of Tromsø – The Arctic University of Norway
  • Lund University
  • Albert Einstein College of Medicine
  • Johns Hopkins University

Research output: Contribution to journalArticlepeer-review

Abstract

IMPORTANCE: The prevalence of cardiometabolic multimorbidity is increasing. OBJECTIVE: To estimate reductions in life expectancy associated with cardiometabolic multimorbidity. DESIGN, SETTING, AND PARTICIPANTS: Age- and sex-adjusted mortality rates and hazard ratios (HRs) were calculated using individual participant data from the Emerging Risk Factors Collaboration (689 300 participants; 91 cohorts; years of baseline surveys: 1960-2007; latest mortality follow-up: April 2013; 128 843 deaths). The HRs from the Emerging Risk Factors Collaboration were compared with those from the UK Biobank (499 808 participants; years of baseline surveys: 2006-2010; latest mortality follow-up: November 2013; 7995 deaths). Cumulative survival was estimated by applying calculated age-specific HRs for mortality to contemporary US age-specific death rates. EXPOSURES: A history of 2 or more of the following: diabetes mellitus, stroke, myocardial infarction (MI). MAINOUTCOMESANDMEASURES: All-cause mortality and estimated reductions in life expectancy. RESULTS: In participants in the Emerging Risk Factors Collaboration without a history of diabetes, stroke, or MI at baseline (reference group), the all-cause mortality rate adjusted to the age of 60 years was 6.8 per 1000 person-years. Mortality rates per 1000 person-years were 15.6 in participants with a history of diabetes, 16.1 in those with stroke, 16.8 in those with MI, 32.0 in those with both diabetes and MI, 32.5 in those with both diabetes and stroke, 32.8 in those with both stroke and MI, and 59.5 in those with diabetes, stroke, and MI. Compared with the reference group, the HRs for all-cause mortality were 1.9 (95% CI, 1.8-2.0) in participants with a history of diabetes, 2.1 (95% CI, 2.0-2.2) in those with stroke, 2.0 (95% CI, 1.9-2.2) in those with MI, 3.7 (95% CI, 3.3-4.1) in those with both diabetes and MI, 3.8 (95% CI, 3.5-4.2) in those with both diabetes and stroke, 3.5 (95% CI, 3.1-4.0) in those with both stroke and MI, and 6.9 (95% CI, 5.7-8.3) in those with diabetes, stroke, and MI. The HRs from the Emerging Risk Factors Collaboration were similar to those from the more recently recruited UK Biobank. The HRs were little changed after further adjustment for markers of established intermediate pathways (eg, levels of lipids and blood pressure) and lifestyle factors (eg, smoking, diet). At the age of 60 years, a history of any 2 of these conditions was associated with 12 years of reduced life expectancy and a history of all 3 of these conditions was associated with 15 years of reduced life expectancy. CONCLUSIONS AND RELEVANCE: Mortality associated with a history of diabetes, stroke, or MI was similar for each condition. Because any combination of these conditions was associated with multiplicative mortality risk, life expectancy was substantially lower in people with multimorbidity.

Original languageEnglish
Pages (from-to)52-60
Number of pages9
JournalJAMA
Volume314
Issue number1
DOIs
Publication statusPublished - 7 Jul 2015
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Association of cardiometabolic multimorbidity with mortality'. Together they form a unique fingerprint.

Cite this